focus -WSS

focus

author：focus 2025-08-28 06:18:48 - browse：798

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： STAT Summit: GSK CEO on pharma giant's new direction

hotspot

WSS

STAT Summit: GSK CEO on pharma giant's new direction

Medicare Advantage's lean provider networks lead CMS complaints

Medicare Advantage's lean provider networks lead CMS complaints

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Take antibiotics after sex, CDC recommends for certain risk groups

Studies point to risks of excluding people with obesity from drug trials

focus

focus

hotspot

Cancer drug shortages should be causing more outrage

A new initiative will help leaders fight the next pandemic

Drug repurposing or repositioning? The language matters

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

State Dept. review finds Biden bears some blame for Afghanistan failures

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Malaria cases in Florida and Texas: Here’s what you need to know

The EU Joint Clinical Assessment needs to live up to its promise

Alkermes shareholders re

Studies point to risks of excluding people with obesity from drug trials

knowledge

STAT Summit: Michael J. Fox on progress in Parkinson's research

Impact of Dobbs ruling felt at reproductive medicine meeting

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Why health workers in Gaza are injured or die at high rates

CMS got Medicare Advantage quality rating wrong, judge rules

How climate

hotspot

knowledge

hotspot

hotspot